Menu Search
Equities

Pharmadrug Inc

LMLLF:PKC

Pharmadrug Inc

Actions
  • Price (USD)0.0291
  • Today's Change0.003 / 10.63%
  • Shares traded396.15k
  • 1 Year change-42.99%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 20:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-13.20m
  • Incorporated2011
  • Employees--
  • Location
    Pharmadrug Inc77 King St. West, Suite 2905TORONTO M5K 1H1CanadaCAN
  • Phone+1 (647) 202-1824
  • Fax+1 (416) 765-0029
  • Websitehttps://pharmadrug.ca/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		 since
announced		Transaction
value
Securedose Synthetics IncDeal completed27 Oct 202327 Oct 2023Deal completed-12.50%--
Data delayed at least 15 minutes, as of May 22 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.